Two independent studies have linked neuronal injury, inside or outside the brain, to cancer progression and offer new biomarkers and strategies for prevention. While cerebral cancer cells damage axons and drive tumor development, in other types of cancer affecting other organs, nerve disruption caused by tumor proximity triggers inflammation and a suppressive environment that may also be associated with immunotherapy resistance. Read More
The signaling of ephrin B (EphB) has been shown to be involved in the progression of metabolic disorders, among others. In this context, researchers from Texas Tech University Health Sciences Center have developed a pan-EphB inhibitor – STA-013 – for the treatment of metabolic syndrome. Read More
Palobiofarma SL has announced the successful completion of an industrial research project investigating dual antagonist compounds targeting adenosine A2A and histamine H3 receptors for the treatment of Parkinson’s disease. Read More
Tidewave Bio has completed an FDA Interact meeting that provided regulatory feedback as the company advances its lead program, TBC-1, toward IND-enabling studies. The company is developing a universal, off-the-shelf immunotherapy platform that is converted into a patient-specific precision medicine in real time using a tumor biopsy. Read More
Gluetacs Therapeutics (Shanghai) Co. Ltd. has synthesized molecular glue degraders comprising a cereblon (CRBN) binding moiety acting as protein degradation inducers reported to be useful for the treatment of anemia, cancer, diabetes, infections, transplant rejection, inflammation, autoimmune and sarcoidosis, among others. Read More
Replicate Bioscience Inc. and Novo Nordisk A/S have entered into a multiyear research collaboration that will leverage Replicate’s novel self-replicating RNA (srRNA) platform to develop new therapeutic candidates to treat obesity, type 2 diabetes and other cardiometabolic diseases. Read More
The FDA has granted orphan drug designation to Vanda Pharmaceuticals Inc.’s VGT-1849B, a selective peptide nucleic acid-based JAK2 inhibitor for the treatment of polycythemia vera (PV). Read More
Deciphera Pharmaceuticals LLC has disclosed serine/threonine-protein kinase ULK1 and serine/threonine-protein kinase ULK2 inhibitors reported to be useful for the treatment of cancer. Read More
Haisco Pharmaceutical Group Co. Ltd. has identified crystalline forms of poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer. Read More
Tyra Biosciences Inc. recently presented the design and preclinical characterization of TYRA-200, an oral small-molecule FGFR1/2/3 tyrosine kinase inhibitor (TKI) that shows high potency against all common mutant forms of FGFR2 and holds potential for the treatment of cancers driven by FGFR2 alterations. Read More
Luye Innomind Pharma Shijiazhuang Co. Ltd. has divulged salts of 5-HT2A receptor inverse agonists with improved stability reported to be useful for the treatment of bipolar disorder, depression, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, sleep disorders, anxiety disorders and schizophrenia. Read More
Guangzhou Fermion Technology Co. Ltd. has described non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of allergy, autoimmune disease, cancer, dermatological disorders, dry eye, myelofibrosis, neurological disorders and transplant rejection, among others. Read More
Moma Therapeutics Inc. has released data regarding their Werner syndrome helicase (WRN) inhibitor MOMA-341 for the potential treatment of cancer. MOMA-341 is a potent and selective WRN inhibitor, the action of which is through covalent ligation. Read More
